Cargando…

Nasal Vaccine Delivery

The mucosal surfaces represent the major site of entry of many pathogens, and major challenges in vaccine development include safety and stability in a suitable dosage form. Micro- and nanocarrier-based delivery systems as nasal vaccines induce humoral, cellular, and mucosal immunity. The nasal rout...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramvikas, M., Arumugam, M., Chakrabarti, S.R., Jaganathan, K.S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151830/
http://dx.doi.org/10.1016/B978-0-323-39981-4.00015-4
_version_ 1783521339628322816
author Ramvikas, M.
Arumugam, M.
Chakrabarti, S.R.
Jaganathan, K.S.
author_facet Ramvikas, M.
Arumugam, M.
Chakrabarti, S.R.
Jaganathan, K.S.
author_sort Ramvikas, M.
collection PubMed
description The mucosal surfaces represent the major site of entry of many pathogens, and major challenges in vaccine development include safety and stability in a suitable dosage form. Micro- and nanocarrier-based delivery systems as nasal vaccines induce humoral, cellular, and mucosal immunity. The nasal route of vaccination could also offer immunity at several distant mucosal sites (oral, rectal, vaginal, and pulmonary), which is considered a simplified and cost-effective mode of vaccination with enhanced patient compliance. Most of the nasal vaccine delivery systems in the form of microparticulates, nanoparticulates, and liposomes are currently under development and prove to offer immunity in animal models. The importance and potential of the nasal route of administration for vaccines is unexplored, and this chapter outlines the opportunities, challenges, and potential delivery solutions to facilitate the development of improved nasal vaccines for infectious diseases.
format Online
Article
Text
id pubmed-7151830
institution National Center for Biotechnology Information
language English
publishDate 2017
record_format MEDLINE/PubMed
spelling pubmed-71518302020-04-13 Nasal Vaccine Delivery Ramvikas, M. Arumugam, M. Chakrabarti, S.R. Jaganathan, K.S. Micro and Nanotechnology in Vaccine Development Article The mucosal surfaces represent the major site of entry of many pathogens, and major challenges in vaccine development include safety and stability in a suitable dosage form. Micro- and nanocarrier-based delivery systems as nasal vaccines induce humoral, cellular, and mucosal immunity. The nasal route of vaccination could also offer immunity at several distant mucosal sites (oral, rectal, vaginal, and pulmonary), which is considered a simplified and cost-effective mode of vaccination with enhanced patient compliance. Most of the nasal vaccine delivery systems in the form of microparticulates, nanoparticulates, and liposomes are currently under development and prove to offer immunity in animal models. The importance and potential of the nasal route of administration for vaccines is unexplored, and this chapter outlines the opportunities, challenges, and potential delivery solutions to facilitate the development of improved nasal vaccines for infectious diseases. 2017 2016-10-07 /pmc/articles/PMC7151830/ http://dx.doi.org/10.1016/B978-0-323-39981-4.00015-4 Text en Copyright © 2017 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Ramvikas, M.
Arumugam, M.
Chakrabarti, S.R.
Jaganathan, K.S.
Nasal Vaccine Delivery
title Nasal Vaccine Delivery
title_full Nasal Vaccine Delivery
title_fullStr Nasal Vaccine Delivery
title_full_unstemmed Nasal Vaccine Delivery
title_short Nasal Vaccine Delivery
title_sort nasal vaccine delivery
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151830/
http://dx.doi.org/10.1016/B978-0-323-39981-4.00015-4
work_keys_str_mv AT ramvikasm nasalvaccinedelivery
AT arumugamm nasalvaccinedelivery
AT chakrabartisr nasalvaccinedelivery
AT jaganathanks nasalvaccinedelivery